Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan
Authors' conclusion
This is the first report showing the long-term effects of imeglimin in a real-world setting. We confirmed the glucose-lowering effects of imeglimin. Furthermore, favorable effects of imeglimin on body weight and serum lipids were also suggested.
Study context
- Population
- Patients with T2D who took imeglimin continuously for at least 3 months, Japan
- Participants
- 68 patients
- Outcome
- Change in HbA1c
- Follow-up
- 3, 6 and 12 months after initiation
Methodological detailschart review
- Chart review
Main finding
As reported in the abstract
HbA1c decrease · 3, 6 and 12 months
HbA1c decrease at 3 months
0.7 %
HbA1c decrease at 6 months
1.1 %
HbA1c decrease by 12 months
1.0 %
Observational data: associations, not effects.
Further findings
HbA1c decrease by subgroup
- HbA1c decreased regardless of age, gender, BMI, diabetes duration, renal function and concomitant hypoglycemic agents
Body weight and lipids · during imeglimin treatment
- Significant decreases in body weight, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and non-HDL-C
Original publication
Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan. Diabetes Res Clin Pract. Published 20 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →